Richard Pestell will join CytoDyn Inc. of Vancouver as chief medical officer.
Rob Beck was named Chief Operating Officer of the Leukemia & Lymphoma Society.
The Carnegie Corporation of New York named UCLA oncologist, Antoni Ribas, a “Great Immigrant” as part of a group of naturalized citizens who have made notable contributions to the progress of American society.
Andrea Abbott has joined Fox Chase Cancer Center as an assistant professor in the Department of Diagnostic Imaging.
The fiscal year 2019 spending bill marked up by the House Committee on Appropriations gives NIH a $1.25 billion raise.
After achieving complete regression in several patients with different solid tumor types, Steven Rosenberg is eyeing the biggest prize imaginable—advancing the therapies he has championed for over four decades into the clinic as treatments for commonly occurring cancers.
For more than four decades, Steven Rosenberg's work on tumor infiltrating lymphocytes has met with equal measures of skepticism and cheer—but now, as more patients across multiple cancer types respond to cell transfer immunotherapy, researchers are eager to join the movement Rosenberg indisputably leads.
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.
FDA has limited the use of Tecentriq and Keytruda for patients with locally advanced or metastatic urothelial cancer who are not eligible for cisplatin-containing therapy.
Novartis announced the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion recommending approval of Kymriah (tisagenlecleucel, formerly CTL019)—a one-time treatment that uses a patient's own T cells to fight cancer.
